ZA888674B - Pharmaceutical formulations - Google Patents

Pharmaceutical formulations

Info

Publication number
ZA888674B
ZA888674B ZA888674A ZA888674A ZA888674B ZA 888674 B ZA888674 B ZA 888674B ZA 888674 A ZA888674 A ZA 888674A ZA 888674 A ZA888674 A ZA 888674A ZA 888674 B ZA888674 B ZA 888674B
Authority
ZA
South Africa
Prior art keywords
melphalan
pharmaceutical formulations
hydrochloride
substantially pure
mephalan
Prior art date
Application number
ZA888674A
Other languages
English (en)
Inventor
Stephen William Poole
William Poole Stephen
Timothy Paul Stanley
Paul Stanley Timothy
Geoffrey Divall
Divall Geoffrey
Terence William Packham
William Packham Terence
Joseph Knight
Knight Joseph
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of ZA888674B publication Critical patent/ZA888674B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Catalysts (AREA)
  • Steroid Compounds (AREA)
ZA888674A 1987-11-19 1988-11-18 Pharmaceutical formulations ZA888674B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB878727157A GB8727157D0 (en) 1987-11-19 1987-11-19 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
ZA888674B true ZA888674B (en) 1990-07-25

Family

ID=10627252

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA888674A ZA888674B (en) 1987-11-19 1988-11-18 Pharmaceutical formulations

Country Status (22)

Country Link
US (1) US4997651A (xx)
EP (1) EP0317281B1 (xx)
JP (1) JP2693191B2 (xx)
KR (1) KR970002607B1 (xx)
AT (1) ATE83922T1 (xx)
AU (1) AU619781B2 (xx)
CA (1) CA1341114C (xx)
DE (1) DE3877151T2 (xx)
DK (1) DK172794B1 (xx)
ES (1) ES2052745T3 (xx)
FI (2) FI90204C (xx)
GB (1) GB8727157D0 (xx)
GR (1) GR3007287T3 (xx)
HK (1) HK108994A (xx)
HU (3) HU203197B (xx)
IE (1) IE63996B1 (xx)
IL (1) IL88419A (xx)
LV (1) LV10179B (xx)
NZ (2) NZ239867A (xx)
PT (1) PT89028B (xx)
SG (1) SG73894G (xx)
ZA (1) ZA888674B (xx)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5695751A (en) * 1993-04-08 1997-12-09 Cornell Research Foundation, Inc. Enhancing delivery of large neutral amino acid drugs
US5407672A (en) * 1993-04-08 1995-04-18 Cornell Research Foundation, Inc. Enhancing the anti-tumor effect of melphalan with L-amino acid oxidase
US6020004A (en) * 1997-04-17 2000-02-01 Amgen Inc. Biodegradable microparticles for the sustained delivery of therapeutic drugs
US5980904A (en) * 1998-11-18 1999-11-09 Amway Corporation Skin whitening composition containing bearberry extract and a reducing agent
GB2386066A (en) * 2002-02-28 2003-09-10 Norbrook Lab Ltd Long-acting parasiticidal composition with improved bioavailability comprising a salicylanilide, a further anti-parasitic compound & a polymeric species
WO2004000229A2 (en) * 2002-06-24 2003-12-31 Research Development Foundation Treatment of human multiple myeloma by curcumin
CA2536380A1 (en) 2003-08-26 2005-02-26 Research Development Foundation Osteoclastogenesis inhibitors and uses thereof
US8501818B2 (en) 2005-03-14 2013-08-06 Ceptaris Therapeutics, Inc. Stabilized compositions of alkylating agents and methods of using same
US7872050B2 (en) * 2005-03-14 2011-01-18 Yaupon Therapeutics Inc. Stabilized compositions of volatile alkylating agents and methods of using thereof
ES2727523T3 (es) 2008-03-27 2019-10-16 Helsinn Healthcare Sa Composiciones estabilizadas de agentes de alquilación y métodos de utilización de estas composiciones
AR066943A1 (es) * 2008-06-10 2009-09-23 Eriochem Sa Una composicion farmaceutica de melfalano
US11020363B2 (en) 2009-05-29 2021-06-01 Cydex Pharmaceuticals, Inc. Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
CA2763365C (en) 2009-05-29 2016-09-13 Cydex Pharmaceuticals, Inc. Injectable melphalan compositions comprising a cyclodextrin derivative and methods of making and using the same
AR077384A1 (es) 2010-07-05 2011-08-24 Eriochem Sa Una formulacion farmaceutica inyectable de melfalano.
US8921596B2 (en) * 2010-11-04 2014-12-30 Emcure Pharmaceuticals, Ltd. Process for the preparation of melphalan hydrochloride
PL2701720T3 (pl) 2011-04-28 2017-12-29 Oncopeptides Ab Liofilizowany preparat cytotoksycznych dipeptydów
SI2928463T1 (sl) 2012-10-26 2020-03-31 Oncopeptides Ab Liofilizirani pripravki melfalan flufenamida
EP2970102B1 (en) 2013-03-11 2019-05-08 Biophore India Pharmaceuticals Pvt. Ltd. An improved process for the synthesis of melphalan and the hydrochloride salt
ITMI20130896A1 (it) * 2013-05-31 2014-12-01 Farmabios Spa Processo di purificazione di melphalan
JP2018512394A (ja) * 2015-03-06 2018-05-17 リーディアント・バイオサイエンシーズ・ソシエタ・アノニマＬｅａｄｉａｎｔ Ｂｉｏｓｃｉｅｎｃｅｓ Ｓ．Ａ． 多発性骨髄腫のロネパルスタット併用療法
US10537520B2 (en) * 2015-06-30 2020-01-21 Leiutis Pharmaceuticals Pvt. Ltd. Stable liquid formulations of melphalan
EP3773498B1 (en) * 2018-03-29 2022-06-22 Project Pharmaceutics GmbH Liquid pharmaceutical formulation
US10682326B1 (en) 2019-06-03 2020-06-16 Shilpa Medicare Limited Stable melphalan liquid injectable formulations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB750155A (en) * 1953-03-17 1956-06-13 Nat Res Dev Substituted alanines
US3032585A (en) * 1954-12-03 1962-05-01 Nat Res Dev Process for the production of p-bis-(2-chloroethyl)-aminophenylalanine
DE1292660B (de) * 1963-04-24 1969-04-17 Ural Polytechnitscheskij I Im Verfahren zur Herstellung von p-(Bis-ª‰-chloraethyl-amino)-phenylalanin-hydrochlorid
US4029778A (en) * 1969-01-23 1977-06-14 Aktiebolaget Leo Cortical steroid nitrogen mustard compositions and treatment therewith
RO57195A2 (xx) * 1970-11-30 1974-09-01
FR2285855A1 (fr) * 1974-09-25 1976-04-23 Kohjin Co Composition therapeutique lyophilisee a base de sel de cyclocytidine et son procede de preparation
JPS59186924A (ja) * 1983-04-08 1984-10-23 Kureha Chem Ind Co Ltd ヒト免疫グロブリン結合抗腫瘍剤
US4696814A (en) * 1985-08-21 1987-09-29 Warner-Lambert Company Parenteral phenytoin compositions
JPS62192357A (ja) * 1986-02-19 1987-08-22 Kureha Chem Ind Co Ltd Ｎ−フタロイル−ｐ−ニトロ−Ｌ−フエニルアラニンの製造方法

Also Published As

Publication number Publication date
FI885358A (fi) 1989-05-20
NZ239867A (en) 1992-11-25
FI885358A0 (fi) 1988-11-18
EP0317281A2 (en) 1989-05-24
EP0317281A3 (en) 1989-08-09
EP0317281B1 (en) 1992-12-30
JP2693191B2 (ja) 1997-12-24
DE3877151T2 (de) 1993-07-15
DK646688A (da) 1989-05-20
IE883447L (en) 1989-05-19
PT89028A (pt) 1988-12-01
SG73894G (en) 1994-11-25
ES2052745T3 (es) 1994-07-16
NZ227004A (en) 1992-11-25
KR890007729A (ko) 1989-07-05
US4997651A (en) 1991-03-05
ATE83922T1 (de) 1993-01-15
IL88419A0 (en) 1989-06-30
HU206671B (en) 1992-12-28
AU2574888A (en) 1989-05-25
HUT48198A (en) 1989-05-29
LV10179A (lv) 1994-10-20
AU619781B2 (en) 1992-02-06
FI90204B (fi) 1993-09-30
HU203197B (en) 1991-06-28
IL88419A (en) 1993-03-15
FI102275B1 (fi) 1998-11-13
KR970002607B1 (ko) 1997-03-06
HU9100335D0 (en) 1991-08-28
FI924668A0 (fi) 1992-10-15
FI90204C (fi) 1994-01-10
HU910336D0 (en) 1991-08-28
FI924668A (fi) 1992-10-15
FI102275B (fi) 1998-11-13
GR3007287T3 (xx) 1993-07-30
HK108994A (en) 1994-10-14
JPH01153628A (ja) 1989-06-15
LV10179B (en) 1995-06-20
PT89028B (pt) 1993-02-26
DK172794B1 (da) 1999-07-19
IE63996B1 (en) 1995-06-28
HU207286B (en) 1993-03-29
DK646688D0 (da) 1988-11-18
GB8727157D0 (en) 1987-12-23
DE3877151D1 (de) 1993-02-11
CA1341114C (en) 2000-10-10

Similar Documents

Publication Publication Date Title
ZA888674B (en) Pharmaceutical formulations
IL86782A0 (en) Amino acid derivatives,processes for the preparation thereof and pharmaceutical compositions comprising the same
ES2032898T3 (es) Procedimiento para la fabricacion de una locion topica.
GB2133983B (en) Method for preparing galenic formulations particularly for pharmaceutical, dietary, cosmetic and diagnostic uses
IL68456A0 (en) Pharmaceutical compositions comprising perfluorohydrocarbons as vehicles
PT80752A (en) Process for preparing solid medicament formulations containing dihydropyridines
AU6724581A (en) Plenylpiperazine derivatives of 1,3,4-oxiadiazolylphends
IL85189A (en) Beta-alkyl substituted melatonins,their preparation and pharmaceutical compositions containing them
HUT50787A (en) Process for producing pharmaceutical compositions comprising 4-aryl-4-piperidine-, pyrrolidine- or hexahydroazepincarbinol derivatives or heterocyclic analogs thereof as active ingredient and process for producing the new compounds
HUT54166A (en) Process for producing 1,1-dioxocefem-4-carbothiol acid derivatives and pharmaceutical compositions comprising same as active ingredient
MY105860A (en) Pharmaceutical formulations.
ES8607016A1 (es) Preparado solido de nifedipina
AU6320480A (en) Piperidine derivatives of 4,5-dialkyl-3-hydroxy-pyrrole-2- carboxylic acid esters